Kappa Bioscience Appoints Australian QC Lab ALS Pharmaceutical
27 Mar 2015 --- Kappa Bioscience AS, Oslo, Norway, is pleased to announce that following its successful launch in the Australian market, it has appointed ALS Pharmaceutical as the preferred QC laboratory. ALS Pharmaceutical has received Kappa’s full analytical package on vitamin K2 MK-7 and has successfully implemented the technology.
ALS Pharmaceutical can offer consumer product testing on Vitamin K2 MK-7 for the local and international markets, which may include QC release testing and shelf-life testing following customer’s or internationally recognised protocols.
“After Kappa’s successful application with the TGA and the introduction of Vitamin K2 MK-7 to the Australian market in June 2014, we have been overwhelmed with the positive response and adoption of Vitamin K2 MK-7 into local formulation. It is only fitting to ensure that a local, independent testing facility can provide reliable testing, ensuring both compliance and functionality of this key nutrient,” comments Peter Wisler, VP Sales & Marketing and local Kappa Bioscience AS representative.
Wisler further told NutritionInsight: “The Australian market is highly regulated due to tough entry requirements by the TGA for approval of new ingredients. Kappa has successfully applied and received approval for its K2VITAL, vitamin K2 MK-7 to be used as a functional ingredient in complimentary medicine.
“As of to-date – there are already over 20 formulations containing vitamin K2 MK-7 registered with the TGA, broadly concentrating on bone health, cardiovascular health and proper calcium distribution in general,” he said.
As Scott Colbourne, Business Manager ALS Pharmaceutical NSW, further adds: “Extending our services to include the testing and verification of new ingredients such as Vitamin K2 MK-7 is an ongoing drive of ALS to stay closely connected to market needs & developments. The adoption of the internationally acknowledged testing method for Vitamin K2 MK-7 has given assurances of comparable results between international testing facilities”.
By Kelly Worgan
